Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX

Background/Aims: Although many studies have reported the promising effect of neoadjuvant treatment for borderline resectable pancreatic cancer (BRPC) to increase resectability, only a few studies have recommended the use of first-line chemotherapeutic agents as neoadjuvant treatment for BRPC. The cu...

Full description

Saved in:
Bibliographic Details
Published in:Gut and liver 2021-05, Vol.15 (3), p.466
Main Authors: Yoo Jin Choi, Yoonhyeong Byun, Jae Seung Kang, Hyeong Seok Kim, Youngmin Han, Hongbeom Kim, Wooil Kwon, Do-youn Oh, Woo Hyun Paik, Sang Hyub Lee, Ji Kon Ryu, Yong-tae Kim, Kyungbun Lee, Haeryoung Kim, Eui Kyu Chie, Jin-young Jang
Format: Article
Language:Korean
Subjects:
Neoadjuvant therapy
Pancreatic neoplasms
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aims: Although many studies have reported the promising effect of neoadjuvant treatment for borderline resectable pancreatic cancer (BRPC) to increase resectability, only a few studies have recommended the use of first-line chemotherapeutic agents as neoadjuvant treatment for BRPC. The current study compared clinical outcomes between gemcitabine and FOLFIRINOX (5-fluorouracil, leucovorin, oxaliplatin, and irinotecan) in patients with BRPC. Methods: In this single-center retrospective study, 100 BRPC patients treated with neoadjuvant chemotherapy and resection from 2008 to 2018 were reviewed. Clinical outcomes included overall survival, resectability, and recurrence patterns after gemcitabine or FOLFIRINOX treatment. Results: For neoadjuvant chemotherapy, gemcitabine was administered to 34 patients and FOLFIRINOX to 66. Neoadjuvant radiotherapy was administered to 27 patients (79.4%) treated with gemcitabine and 19 (28.8%) treated with FOLFIRINOX (p
ISSN:1976-2283